D-0357-2025 Class II Ongoing

Recalled by Somerset Therapeutics Private Limited — Bengaluru, N/A

FDA drug recall D-0357-2025 was initiated by Somerset Therapeutics Private Limited on Mar 21, 2025 and is designated Class II. Reason for recall: Lack of Assurance of Sterility: Media fill with bacterial contamination The recall status is ongoing. Affected quantity: 23,960 vials.

Recall details

Product Type
Drugs
Report Date
Apr 16, 2025
Initiation Date
Mar 21, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
23,960 vials

Product description

Haloperidol Decanoate Injection 100mg/mL, 1mL Single-Dose Vial, Rx Only, Manufactured by: Somerset Therapeutics Limited, Kamataka, India, Manufactured for: BluePoint Laboratories NDC 68001-581-41 (individual carton) and NDC 68001-581-48 (5x1 mL cartons)

Reason for recall

Lack of Assurance of Sterility: Media fill with bacterial contamination

Distribution pattern

U.S. Nationwide

Code information

NDC 68001-581-41; A240482A, exp. date 08/2026; NDC 68001-581-48; A240482B, exp. date 08/2026

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0357-2025
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0357-2025. Report a data issue: hello@regdatalab.com.